0

Is the Treatment of Enterobius Vermicularis Co-Infection Necessary to Eradicate Dientamoeba Fragilis Infection?

José A Boga, Susana Rojo, Jonathan Fernández, Mercedes Rodríguez, Carmen Iglesias, Pablo Martínez-Camblor, Fernando Vázquez, Azucena Rodríguez-Guardado

Int J Infect Dis. 2016 Aug;49:59-61.

PMID: 27263118

Abstract:

Objectives:
Dientamoeba fragilis is a pathogenic protozoan of the human gastrointestinal tract with a worldwide distribution, which has emerged as an important and misdiagnosed cause of chronic gastrointestinal illnesses such as diarrhea and 'irritable-bowel-like' gastrointestinal disease. Very little research has been conducted on the use of suitable antimicrobial compounds. Furthermore, higher rates of co-infection with Enterobius vermicularis have been described, suggesting that E. vermicularis could influence the treatment of D. fragilis-infected patients. To study this, the treatment of E. vermicularis and D. fragilis co-infected patients was evaluated.
Methods:
Forty-nine patients with a D. fragilis infection, including 25 (51.0%) patients co-infected with E. vermicularis, were studied. All of them were treated with metronidazole. Patients with E. vermicularis co-infection and/or an E. vermicularis-positive case in the family were treated with mebendazole.
Results:
Metronidazole treatment failure was significantly more frequent in patients with E. vermicularis co-infection and in patients with children in the family.
Conclusions:
Co-infection with E. vermicularis may act as a factor favoring D. fragilis infection by preventing eradication measures. This suggests that both parasites should be treated simultaneously.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP132119110 Mebendazole Related Compound D Mebendazole Related Compound D 132119-11-0 Price
qrcode